Wanbury Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a healthy return on capital (ROCE) of 55.8%
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.1%
- Promoters have been increasing their shareholding - up 3.2pp over 2 years
- Latest quarter profit grew 1200.9% YoY, showing strong momentum
- Operating margins have improved to 11.2% from 7.2%
CONS
- Company has a high debt-to-equity of 3.37x
- Recent results are weak - TTM profit is down 38.0% versus prior year
- A large part of profit comes from other income (41.0% of PBT)
- Receivables are growing faster than sales - a possible quality concern
- Interest coverage is weak at 1.8x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| WANBURY | 239.50 | 19.48 | 837.46 | 0.00 | 13.49 | 1200.87 | 163.18 | 24.46 | 35.97 | 14.98 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117 | 124 | 126 | 133 | 146 | 144 | 146 | 140 | 131 | 161 | 133 | 172 | 163 | |
| 120 | 118 | 119 | 119 | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 | |
| Operating Profit | -3 | 6 | 6 | 14 | 13 | 17 | 21 | 19 | 11 | 20 | 14 | 30 | 24 |
| OPM % | -2.60% | 4.51% | 5.13% | 10.66% | 9.13% | 12.00% | 14.54% | 13.25% | 8.37% | 12.41% | 10.45% | 17.23% | 14.98% |
| 2 | 1 | 0 | -3 | 1 | 1 | 1 | 26 | 1 | 2 | 1 | 2 | 0 | |
| Interest | 3 | 4 | 7 | 8 | 6 | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Profit before Tax | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 |
| Tax % | 2.78% | -25.35% | -7.62% | -10.87% | 6.01% | -2.50% | -0.19% | 0.80% | 0.00% | 1.84% | 5.43% | -6.30% | 0.88% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 |
| -2.22 | -0.27 | -1.00 | 0.31 | 1.43 | 2.25 | 3.14 | 10.28 | 0.32 | 2.44 | 0.38 | 6.18 | 4.12 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 423 | 434 | 371 | 391 | 367 | 393 | 511 | 500 | 578 | 600 | 630 | |
| 391 | 415 | 439 | 378 | 389 | 377 | 479 | 477 | 506 | 532 | 542 | |
| Operating Profit | 32 | 19 | -68 | 13 | -22 | 16 | 32 | 23 | 72 | 68 | 88 |
| OPM % | 7.65% | 4.27% | -18.30% | 3.42% | -5.88% | 3.99% | 6.21% | 4.62% | 12.48% | 11.29% | 13.98% |
| 1 | 90 | 77 | 12 | 129 | 5 | 81 | 0 | 26 | 12 | 5 | |
| Interest | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 37 |
| Depreciation | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 |
| Profit before Tax | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 | 42 |
| Tax % | -0.00% | 0.61% | 1.17% | 0.55% | 0.32% | -1.61% | -0.43% | -1.06% | 0.68% | -3.31% | -2.04% |
| Net Profit | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | 43 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.04 | 1.58 | -3.18 | 17.09 | 9.32 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 9%
- 5 Years:
- 10%
- 3 Years:
- 5%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 25%
- 5 Years:
- -14%
- 3 Years:
- -28%
STOCK PRICE CAGR
- 10 Years:
- 18%
- 5 Years:
- 24%
- 3 Years:
- 59%
- 1 Year:
- -10%
RETURN ON EQUITY
- 10 Years:
- 8%
- 5 Years:
- 17%
- 3 Years:
- 28%
- Last Year:
- 84%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 |
| Minority Interest | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -221 | -176 | -209 | -233 | -169 | -182 | -57 | -67 | -12 | 19 | |
| 333 | 217 | 182 | 252 | 177 | 165 | 71 | 67 | 103 | 167 | |
| Trade Payables | 86 | 140 | 83 | 112 | 122 | 134 | 180 | 149 | 163 | 138 |
| 143 | 205 | 189 | 127 | 120 | 142 | 121 | 117 | 51 | 50 | |
| Total Liabilities | 388 | 409 | 269 | 283 | 275 | 284 | 347 | 298 | 338 | 407 |
| 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | |
| Capital Work in Progress | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 |
| 35 | 34 | 13 | 19 | 12 | 25 | 50 | 22 | 36 | 38 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89 | 114 | |
| Cash & Bank | 7 | 9 | 6 | 5 | 17 | 12 | 25 | 4 | 6 | 13 |
| 151 | 169 | 62 | 77 | 69 | 69 | 102 | 103 | 37 | 36 | |
| Total Assets | 388 | 409 | 269 | 283 | 275 | 284 | 347 | 298 | 338 | 407 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 43 | 43 | 33 | 30 | 44 | 18 | 41 | 20 | 5 | 26 | |
| Cash from Investing | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 |
| Cash from Financing | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 14 | 26 |
| -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-02 - Wanbury Limited has informed the Exchange about Copy of Newspaper Publication: Information regarding 38th Annual General Meeting to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM).
2026-08-31 - Wanbury Limited has informed the Exchange that Record date for the purpose of Meeting is 18-Sep-2026.
2026-08-31 - Wanbury Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026
2026-08-28 - Wanbury Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-13 - Wanbury Limited has informed the Exchange regarding a press release dated August 13, 2026, titled "Press Release regarding EDQM Approval for new product Rivaroxaban API,USFDA DMF Clearances".
2026-08-11 - Wanbury Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Press release on Un-audited Financial Results for the quarter ended 30 June, 2026".
2026-08-11 - Wanbury Limited has informed the Exchange regarding allotment of 27530 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026
2026-08-11 - Wanbury Limited has informed the Exchange about change in Management
2026-08-11 - Wanbury Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
News
Recent coverage and analyst commentary for WANBURY
Loading news…
AI Stock Analyst
Wanbury Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account